Russia’s sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said.
Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy’s Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.
Turkey signs 50 million dose COVID-19 vaccine deal, health minister saysTurkey has signed a contract to buy 50 million doses of COVID-19 vaccine from China’s Sinovac Biotech, Health Minister Fahrettin Koca said on ... Middle East
Coronavirus: WHO sees progressive control of COVID-19 in 2021, cautions on ChristmasThe World Health Organization’s top emergency expert said on Thursday the introduction of a COVID-19 vaccine should allow the world to gain ... Coronavirus
Coronavirus: UAE officials expect vaccine to be available by end of 2020, early 2021Health officials in the United Arab Emirates expect that a coronavirus vaccine will be available on the global market a government health spokeswoman ... Coronavirus
Coronavirus: Five COVID-19 patients killed in India hospital fireA fire broke out early Friday in a privately-run hospital treating coronavirus patients in western India, killing at least five of them and injuring ... Coronavirus